Back to Search Start Over

miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma.

Authors :
Bao RF
Shu YJ
Hu YP
Wang XA
Zhang F
Liang HB
Ye YY
Li HF
Xiang SS
Weng H
Cao Y
Wu XS
Li ML
Wu WG
Zhang YJ
Jiang L
Dong Q
Liu YB
Source :
Oncotarget [Oncotarget] 2016 Apr 19; Vol. 7 (16), pp. 22339-54.
Publication Year :
2016

Abstract

Gallbladder cancer (GBC), the most common malignancy of the bile duct, is highly aggressive and has an extremely poor prognosis, which is a result of early metastasis. As it is regulated being at multiple levels, the metastatic cascade in GBC is complex. Recent evidence suggests that microRNAs (miRNAs) are involved in cancer metastasis and are promising therapeutic targets. In this study, miR-101 was significantly downregulated in tumor tissues, particularly in metastatic tissues. In GBC patients, low miR-101 expression was correlated with tumor size, tumor invasion, lymph node metastasis, TNM stage, and poor survival. Moreover, miR-101 was an independent prognostic marker for GBC. Additionally, miR-101 inhibited GBC cell proliferation, migration, invasion, and TGF-β-induced epithelial-mesenchymal transition (EMT) in vitro and in vivo. Mechanistically, the gene encoding the zinc finger protein X-linked (ZFX) was identified as a direct target of miR-101. More importantly, miR-101 significantly reduced activation of the MAPK/Erk and Smad signaling pathways, resulting in inhibition of TGF-β-mediated induction of EMT. Altogether, our findings demonstrate a novel mechanism by which miR-101 attenuates the EMT and metastasis in GBC cells and suggest that miR-101 can serve as a potential biomarker and therapeutic target for GBC management.<br />Competing Interests: All authors confirm that there are no conflicts of interest to declare.

Details

Language :
English
ISSN :
1949-2553
Volume :
7
Issue :
16
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
26968949
Full Text :
https://doi.org/10.18632/oncotarget.7970